• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Tumor size, chemoembolization response may predict hepatocellular carcinoma recurrence

byRehan SaiyedandChaz Carrier
May 9, 2014
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD 

1. In patients with hepatocellular carcinoma who underwent liver transplantation, response to transarterial chemoembolization and radiologic size of tumor were both shown to independently predict rates of recurrence. 

2. Patients with no response to chemoembolization and a radiologic tumor size greater than 3 cm had a recurrence rate of 35.8% compared with 1.9% for patients responding to chemoembolization and a tumor size less than 3 cm. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Liver transplantation has played an increasing role in the treatment of hepatocellular carcinoma (HCC). Recurrence following transplantation remains an issue, however, and pre-operative identification of patients at a higher risk for recurrence is limited. This study aimed to identify pre-operative factors to predict rates of HCC recurrence in patients after liver transplantation. Through multivariate analysis, the authors found that a lack of tumor responsiveness to transarterial chemoembolization (TACE) and radiologic tumor size greater than 3 cm were both independent predictors of HCC recurrence. Vascular invasion of the tumor had the strongest association with recurrence but such information is not known pre-operatively, limiting its predictive value. This study provides a means by which to identify patients who are at higher risk of HCC recurrence following liver transplantation. The true utility of such pre-transplant identification is limited by the ethical dilemma in preferentially selecting patients for transplants who lie in the theoretical “lower-risk” group.  That said, there is certainly value in identifying patients with a high risk of recurrence as it would allow for more extensive pre-transplant therapy. This study is limited by selection bias imposed by its retrospective nature as only patients who were treated with TACE and had sufficient time for pre-transplantation radiologic follow-up were included in the analysis.

Click to read the study in the American Journal of Transplantation

RELATED REPORTS

High intake of sugar-sweetened beverages is associated with increased risk of hepatocellular carcinoma

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

Relevant Reading: Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria–selection parameter for liver transplantation

In-Depth [retrospective cohort]: 173 patients with HCC who received a liver transplant were selected for inclusion into the study if they underwent pre-transplant TACE along with radiologic follow-up. Patient’s response to TACE was assessed using modified response evaluation criteria in solid tumors (mRECIST) and patients were accordingly grouped as “responders” or “non-responders.”  mRECIST response categories are organized by the extent of arterial invasion of the tumor. Response to TACE was shown to be predictive of HCC recurrence. 5-year recurrence was 5.3% in the “responder” group compared to 17.6% in the in the non-responders. Tumor size greater than 3 cm was also independently predictive of HCC recurrence. The rate of recurrence in patients who were non-responders to TACE and had a tumor size grater than 3 cm was 35.8%, 10.8% for patients who were non-responders but who had a tumor size less than 3 cm, 11.9% for patients who were responders with a tumor size greater than 3 cm, and 1.9% for patients who responded to TACE and had a tumor size less than 3 cm (log-rank, p=.0007).

More from this author: Decreased breast cancer recurrence and mortality following post-mastectomy radiotherapy, Increased incidence of stroke found after aortic valve replacement

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: chemoembolizationhepatocellular carcinomatumor
Previous Post

Gender differences in white matter integrity may affect post-traumatic brain injury

Next Post

Exercise associated with decreased Cesarean risk

RelatedReports

Sugary drinks and liver cancer collage: an engraved liver beside a glass of dark fizzy drink with ice and rising bubbles
All Specialties

High intake of sugar-sweetened beverages is associated with increased risk of hepatocellular carcinoma

June 19, 2026
2 Minute Medicine AI Roundup editorial illustration
AI Roundup

2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]

July 2, 2025
Liver cancer immunotherapy collage: an engraved liver and gallbladder with round immune cells at its edge and a potted fern
Chronic Disease

Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer

August 27, 2025
Liver cancer immunotherapy collage: an engraved liver and gallbladder with round immune cells at its edge and a potted fern
Chronic Disease

Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma

March 13, 2025
Next Post

Exercise associated with decreased Cesarean risk

Medical liability system presents hurdles to injured patients

Key predictors of recurrence and survival for Merkel Cell Carcinoma elucidated

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation
  • CDC reports increasing early-season influenza activity and at least 900 deaths nationwide
  • A concentrated exposure therapy intervention may be more effective than digital cognitive behavioural therapy in obsessive-compulsive disorder
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.